bioRxiv Science⌕ Search

bioRxiv · 10.1101/2023.11.06.565860

Investigating and Identifying Traditional Medicinal Plant Antioxidants: New Frontiers in Treating Age-related Maladies Associated with Oxidative Stress

Abstract

Oxidative stress is regarded as an imbalance between pro-oxidant and antioxidant species that can result in cellular inflammation associated with illnesses including cancers and cognitive decline. This study investigated medicinal plant extracts for the presence of natural bioactive compounds to explore their antioxidant properties and potential therapeutic relevance in conditions related to oxidative stress. Extracts were created using water as a solvent and compared in triplicate to the positive control quercetin (1 mg/mL) in a 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay; all extracts were serially diluted from 10 mg/mL creating 8 distinct concentrations. Absorbance readings were compared before and after DPPH administration. At the highest concentration, all extracts demonstrated absorbance change factors <10% relative to the DPPH negative control. This result clearly demonstrated antioxidant activity, as lesser relative absorbance changes indicated greater neutralization of violet DPPH into lighter diphenylpicryl hydrazine via free radical scavenging. Most notably, at lowest concentration, Averrhoa carambola and Psidium guajava represented the least relative absorbance changes at 14.17% and 10.39%, rivaling quercetins antioxidant activity- a statistically significant result (p < 0.05). LC-MS/MS analysis of these most potent extracts identified quercetin and kaempferol in Psidium guajava and vitexin-2-O-rhamnoside, isovitexin, saponarin, and an additional flavonoid glycoside in Averrhoa carambola. Such compounds may offer potential pharmacological effects, for example, vitexin-2-O-rhamnoside and isovitexin have demonstrated anticancer, antidiabetic, neuroprotective, and cardioprotective properties in part through oxidative stress reduction. Future research should corroborate compound effects in human cell culture models, as prior studies are often limited to non-human tissues. INTRODUCTIONA medicinal plant is a plant that "contains substances that can be used for therapeutic purposes or which are precursors for the synthesis of useful drugs."1 Medicinal plants contain different classes of potentially bioactive compounds, including, but not limited to peptides, alkaloids, phenylpropanoids, polyketides, and terpenoids.2 Such compounds have alleged and in certain cases documented anticancer, anti-inflammatory, antioxidant, antibacterial, antipyretic, vasodilatory, stimulant, and/or more properties that have been historically used in traditional medicine.1,3 Evidence suggests that medicinal plants have been used for at least 60,000 years in places including what would be modern-day Iraq.4 Medicinal plants are still used all around the world today; Dr. Tedros Adhanom Ghebreyesus of the WHO says "For many millions of people around the world, traditional medicine is the first port of call to treat many diseases."5 In addition, the prevalence of medicinal plants is evident in developed countries too, with the medicinal plant trade between India and China accounting for two to five billion dollars annually.1 However, many of these traditional treatments receive significant scrutiny from modern medicine and societys decreasing reliance on plant-derived drugs. While such scrutiny proves accurate in many cases, several traditional medicinal plants have been shown to offer bioactive compounds that are used as a standard medical practice. This includes morphine, "a natural alkaloid that is derived from resin extracts from the seeds of the opium poppy,"3 which is utilized in clinical settings for its profound analgesic effects,3 and quinine, an antimalarial drug derived from Cinchona officinalis bark.6 The current research project presented herein will serve to test traditional medicinal plant compounds to determine if their claims of relevance can be substantiated and to explore their potential effects on biological organisms, specifically regarding their antioxidant properties and ability to eliminate free radicals. Free radicals are unstable molecular species with unpaired electrons,7 and can contribute to oxidative stress in organisms. Oxidative stress "is considered as an imbalance between pro- and antioxidant species, which results in molecular and cellular damage."8 Examples of known antioxidants include the polyphenol quercetin, which is often used as a positive control for its relative strength in reducing free radicals.9 Demonstrated efficacy of these medicinal plants could provide potential preventative therapies for age-related illnesses and other maladies associated with oxidative stress, including cancers and cognitive decline.8,9 RESEARCH QUESTIONS AND PURPOSEDo the traditional medicinal plants under investigation contain bioactive compounds with antioxidant properties capable of neutralizing free radicals in a 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay? How does the efficacy of the plant extracts compare to the positive control, quercetin, and the associated samples in terms of antioxidant activity as measured by the DPPH assay? Do the extract compounds identified via LC-MS/MS analysis offer potential therapeutic relevance in modern medicine? With our research, we aimed to identify bioactive compounds within medicinal plants, determine if such medicinal plants and their bioactive compounds have applications in modern medical treatments, and ensure medicinal plants are being used safely and accurately under the support of sound scientific evidence.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Gammell, F., Gangji, D., Leibovitz, E., Bertin, M. J.. 2023-11-08. Investigating and Identifying Traditional Medicinal Plant Antioxidants: New Frontiers in Treating Age-related Maladies Associated with Oxidative Stress. https://doi.org/10.1101/2023.11.06.565860

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Conjunctive Targeting Links Drug Synergy to Emergent Proteome Structural States

Combinatorial therapies are widely used in the treatment of acute myeloid leukemia (AML) to address disease heterogeneity, adaptive resistance, and rewired signaling and metabolic states. Yet drug prioritization remains largely guided by clinical or phenotypic evidence, while the molecular mechanisms underlying effective drug combinations remain incompletely defined. To narrow this gap, we developed Combinatorial high-ratio Partial proteolysis with reference PRoteome Analysis (CoPPRA), a structural proteomics workflow based on limited proteolysis of cell lysates that profiles drug-associated changes in regional protein accessibility at peptide-level resolution. Here, we applied CoPPRA to ruxolitinib and ulixertinib, individually and in combination, in AML-related cell lysates. Our findings extend conjunctive targeting (CT), a recently proposed mechanism of combinatorial drug action in which combined exposure produces protein targeting patterns not observed with either drug alone. Previously identified through combination-associated changes in protein solubility/stability, CT is examined here at peptide-level resolution through regional differences in proteolytic accessibility. The ruxolitinib-ulixertinib combination produced broad peptide-level accessibility changes, including a subset meeting the predefined criteria for CT. CT candidates predominantly exhibited regional accessibility changes, with altered peptide regions occurring against comparatively small changes across the remaining quantified peptides from the same proteins. MAP2K1 and ATP6V1G1 showed pronounced differences between overlapping peptide sequences, highlighting localized variation in combination-associated accessibility, including an ATP6V1G1 peptide mapping to an annotated helical region. Combination-associated increases in peptide signals were also observed in PIK3R1, BRD4, and PTPN11, linking regional accessibility changes to signaling and transcriptional regulators relevant to AML. Functional enrichment and network analyses further implicated nucleotide and glucose metabolism, ficolin-1-rich granules, ribosome-associated processes, and phagocytic vesicles. These results extend conjunctive targeting from protein-level solubility/stability changes to regional differences in proteolytic accessibility, showing that combination-associated effects can be concentrated within specific peptide regions rather than distributed uniformly across proteins. More broadly, CoPPRA provides a peptide-resolved approach for investigating the molecular features of combinatorial drug action and prioritizing protein regions for subsequent mechanistic validation.

biochemistry↗

Structural and biochemical characterisation of an iterative GCN5-related N-acetyltransferase required for fungal siderophore tailoring

Siderophore-mediated iron acquisition is essential for fungal survival, particularly under iron-limiting conditions. In Aspergillus fumigatus, SidG, a member of the GCN5-related N-acetyltransferase (GNAT) superfamily, catalyses the final step in the biosynthesis of the extracellular siderophore triacetylfusarinine C (TAFC) through sequential acetylation of the precursor fusarinine C (FsC). However, the timing, catalytic mechanism, and functional significance of this modification are not fully understood. Here, we reconstituted SidG activity in vitro and combined native mass spectrometry, X-ray crystallography, molecular dynamics simulations, and site-directed mutagenesis to investigate its catalytic properties. Our analyses demonstrate that SidG selectively binds acetyl-CoA from the cellular milieu and iteratively acetylates the FsC scaffold prior to iron chelation. Structural, biochemical, and molecular dynamics analyses support a direct transfer mechanism, identify key catalytic residues, and demonstrate the strict selectivity of SidG for short-chain acyl-CoA donors. Together, these findings establish the molecular basis for SidG-dependent siderophore tailoring and expand our understanding of GNAT-catalysed transformations in fungal natural product biosynthesis.

biochemistry↗

Reconstitution of +1 nucleosome transcription reveals coordinated functions of SAGA, Mediator, and TFIIH

The +1 nucleosome has emerged as a key regulator of eukaryotic transcription, but how it controls transcription initiation remains poorly understood. Here we reconstitute transcription through the +1 nucleosome using eleven purified yeast factors: RNA polymerase II (Pol II), the six general transcription factors (GTFs), TFIIS, the activator Pho4, and the SAGA and Mediator complexes. The system recapitulates key features of regulation observed in vivo. SAGA, acting with Pho4, directs pre-initiation complex (PIC) assembly to the correct position through its TBP-loading activity. Mediator stimulates transcription when the +1 nucleosome imposes a barrier to PIC formation, consistent with stabilization of productive TFIIH-DNA engagement. Contrary to the prevailing model, SAGA remains bound to the PIC after TBP loading and acetylates the +1 nucleosome within the assembled complex. The isolated PIC-Mediator-SAGA-nucleosome complex is transcriptionally active, and the repressive effect of the nucleosome is relieved by the DNA translocase activity of Ssl2, the TFIIH subunit that opens promoter DNA. TFIIH thus couples promoter melting to remodeling of the +1 nucleosome.

biochemistry↗